Your moves

Bristol Myers Squibb has announced the appointment of Guy Oliver as General Manager for the company in the UK and Ireland.

In this role, he will lead the UK and Ireland commercial affiliate as it enters a period of renewal, transforming its product portfolio through its mission to help patients prevail over serious disease.

Guy will also sit on the European Markets Leadership Team reporting to Monica Shaw, Senior Vice President and Head of European Markets.

Guy elaborated: “I’m delighted to be joining Bristol Myers Squibb at this exciting time. I look forward to working with the team to deliver on our bold ambitions to deliver more medicines to patients in the UK and Ireland.

“I’m looking forward to joining a thriving and inclusive culture where we can learn from and empower each other to do great things.”

Guy joins Bristol Myers Squibb from Ipsen, where he served as General Manager UK and Ireland. Previously, Guy worked at Novartis for 16 years, holding several senior positions across different functions and geographies.

Hugues Hervouet has been appointed as Sciensus’ Chief Technology Officer.

He joins Sciensus having recently served as Senior Vice President and Chief Information Officer at Shutterstock, a leading global technology provider offering high-quality digital content, tools and services.

Hugues brings over 20 years of experience in the media and technology industries to his new role, having spent time in a variety of leadership roles at Time Inc., a multi-platform global media company and most of his career at Time Warner Inc., a multinational media and entertainment conglomerate.

Hugues will become a key member of Sciensus’ Executive Board to lead the technology function, partnering with senior leaders, to set and execute the company’s digital vision and strategy and oversee the development of its technical products and services. He will be relocating to the UK from New York to assume his new role with Sciensus.

Hugues enthused: “I am delighted to join Sciensus and offer my deep expertise in delivering advanced technology solutions that maximise efficiency, enhance performance, optimise processes and deliver growth. Enhancing the company’s technology function will boost Sciensus’ digital offerings, enhance patient support and elevate patient outcomes overall.”

SPT Labtech has announced the appointment of Rob Walton as Chief Executive Officer, succeeding former CEO David Newble.

Rob joins SPT Labtech from GE Healthcare, where he served as President & CEO for EMEA. Prior to that, he led the Asia Pacific region, based in Singapore.

He also brings expertise in product management and R&D from his roles as Global General Manager for the Ultrasound Primary & Affordable Care business based out of the UK, and the Respiratory Care business based out of the USA. His pre-GE experiences included engineering and operations leadership at Ford and Unilever, and strategy consulting at Bain & Company.

Rob commented “I am excited to join SPT Labtech to help drive the next phase of growth for the business. SPT Labtech has an exceptional portfolio of technologies, which are uniquely positioned to support the future of life sciences research. We have a top class team and it is an honour to lead such an accomplished group of people.”

Michael Bauer, Global Co-Head of Healthcare at EQT stated "We are thrilled to welcome Rob to SPT Labtech. His appointment stands as a clear testament to SPT Labtech's exceptional products and growth prospects as well as EQT's governance model. We are very much looking forward to the cooperation."

Quotient Sciences has announced major changes to its commercial and scientific executive leadership team, strengthening its position as a global leader in the sector.

New appointments include Dr Andrew Lewis (pictured) as Chief Scientific Officer, Kieron Hall as Chief Marketing Officer and Eric Bironneau as Chief Business Officer.

Andrew has responsibility for the company’s scientific and technological innovation.
Kieron’s appointment as Chief Marketing Officer will see him lead the company’s strategic and growth initiatives and marketing organisation.

Eric has joined the company as Chief Business Officer, with responsibility for Quotient Sciences’ commercial organisation across drug substance, drug product and translational pharmaceutics commercial lines.

Aspire Pharma has announced Dr Andriy Krendyukov as its Chief Medical Officer, signalling a key step in company commitment to healthcare innovation.

Andriy has over 25 years in the healthcare system and pharmaceuticals environment, brings a wealth of expertise across therapeutic areas including oncology, neurology, cardiology, endocrinology and COVID-19.

He has held significant roles across different geographies in global and biotech companies such as Servier, Merz, Sandoz/Novartis and Apogenix.

In his role, Andriy will lead the Medical Office, driving Scientific and Regulatory Affairs, R&D, Clinical Operations, Safety and Pharmacovigilance, Quality and Compliance, ensuring Aspire Pharma remains at the forefront of medical advancement and patients access to care.

Meanwhile, Jonathan Chambers has recently joined Aspire Pharma as Senior Vice President – Scientific Affairs, to lead on the R&D, Compliance, Regulatory and Scientific Affairs functions.

Jonathan brings with him a wealth of experience in clinical development, scientific affairs and new product development. This includes clinical R&D leadership skills to deliver highly successful projects, across a variety of therapeutic areas, from specialty care to generic products.

He joins Aspire after working as a Consultant Vice President (VP) at Mereo Biopharma. His previous experience also includes working as European Medical Director at Otsuka Pharmaceuticals and Associate Director Operations, ACE Region, for Kite Pharma.

Cambridge Cognition has announced the appointments of Alex Livingstone-Learmonth as Chief Commercial Officer and Annabelle Miles as Head of Marketing.

These additions mark a significant step as the company continues strengthening its senior leadership team in pursuit of its ambitious growth strategy.

Alex joins Cambridge Cognition with a wealth of sector experience, having worked in the clinical trial technology, services and solutions industry for over 20 years.

Having previously held the role of Vice President at Calyx and Signant Health (initially CRF Health), Alex’s background complements Cambridge Cognition’s commercial model and his experience in promoting clinical trial solutions will be instrumental as the Group continues to focus on delivering profitable growth.

Annabelle started her career at M&C Saatchi and McCann Worldwide, accumulating over ten years of experience in advertising and marketing. During her tenure at FundamentalVR, a health VR start-up, she established a comprehensive marketing function over five years.

Her most recent position at Huma involved spearheading a results-driven lead-generation strategy for marketing healthcare solutions and clinical trials.

Alex and Annabelle will play vital roles in supporting the company’s growth strategy, implementing processes to build the orderbook, increasing awareness and brand exposure for its market leading offering and technology.

The British In Vitro Diagnostic Association (BIVDA) has appointed Helen Dent as Chief Executive, following a successful period as Interim Chief Executive.

Helen will lead BIVDA in championing the medical diagnostics industry to politicians, policymakers, media and relevant stakeholders, and in supporting members to improve patient outcomes.

Helen’s first act as Chief Executive was to launch BIVDA’s new strategy at the organisation’s annual general meeting last Wednesday.

Helen, who previously spent over three years as Chief Operating Officer at BIVDA, brings over twenty years of industry experience to the business. Prior to joining BIVDA, she worked at a senior level at Abbott Diagnostics in the UK and Europe.

She has experience as National Contracts Manager at NHS Blood and Transplant, Pharmacy Buyer for Surrey and Sussex NHS Supply Management Confederation, and the NHS Purchasing and Supply Agency.

Helen said; “I'm thrilled to embark on this new role and lead BIVDA in shaping policy and delivering our new strategy at this crucial time for our members. It's my priority to ensure members’ voices are not only heard, but also magnified to senior figures across the Government and NHS."

Your Moves

Mover of the Month